Analysis of 2-cyano-1-methyl-3-[4-(4-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl phenyl]guanidine in dog plasma by liquid-solid extraction and reversed-phase high-performance liquid chromatography.
A method for the determination of 2-cyano-1-methyl-3-[4-(4-methyl-6-oxo-1,4,5,6-tetrahydropyridazin- 3- yl)phenyl]guanidine (SK&F94836, 1) in plasma is presented. The method involves liquid-solid extraction of the drug by C18 cassettes, with subsequent elution by an AASP LC module for determination by HPLC with UV detection. The assay is rapid, precise, accurate, and specific. The between-day CV values over the concentration range 50-500 ng/mL are 4% or less; this rises to 8% at 25 ng/mL. The corresponding between-day bias is less than 1% over the same range of concentrations. The limit of quantification is 25 ng/mL and the assay can be used for measuring 1 in samples from preclinical studies following either oral or intravenous administration of the compound.
Pearce
J C
JC
Department of Drug Analysis, Smith Kline and French Research, Welwyn, Herts, U.K.
Leavens
W J
WJ
McDowall
R D
RD
D000284:Administration, Oral; D000818:Animals; D002851:Chromatography, High Pressure Liquid; D004285:Dogs; D006146:Guanidines / Q000008:administration & dosage / Q000097:blood*; D007262:Infusions, Intravenous; D011724:Pyridazines / Q000008:administration & dosage / Q000097:blood*; D013056:Spectrophotometry, Ultraviolet
D006146:Guanidines; D011724:Pyridazines; C056215:siguazodan